S-1/A·October 20, 2026 at 6:09 AM EDT·2 sources
Pfizer ends Phase 2 autoimmune study; Lycia aims for $227M IPO
Outlets covering it2 in 5 hours
Oct 20, 10 AMOct 20, 2 PM
What happened
- Lycia Therapeutics, Inc. filed an amended S-1/A registration statement with the SEC on October 20, 2026.
- The filing relates to a proposed initial public offering; terms were not provided in the source.
Why it matters
The amended filing gives ECM, venture investors and healthcare professionals an updated view of Lycia Therapeutics’ potential public-market financing. No offering size or terms were disclosed.
Deal terms
ipo
Lycia Therapeutics, Inc.
Value
—
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Timeline
- Form S-1/AOct 20Lycia Therapeutics, Inc. files to go public (amended)
- First reported by Endpoints NewsOct 20Pfizer ends Phase 2 autoimmune study; Lycia aims for $227M IPO
Who is involved
Pfizer ends Phase 2 autoimmune study; Lycia aims for $227M IPOLycia Therapeutics, Inc.targetSEC
CompanyAgency
Sources (2)
- SEC EDGAROct 20Lycia Therapeutics, Inc. files to go public (amended)
- Endpoints NewsOct 20Pfizer ends Phase 2 autoimmune study; Lycia aims for $227M IPO
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.